Stock fact sheet · data as of
Insulet Corp. (PODD): fair value, margin of safety and Wheel Score
Healthcare · Medical - Devices · United States · High Growth
Is PODD undervalued?
PODD closed at 133.93 on 16 Oct 2026, 13% below the GLS average fair value of 153.23 from 7 models (4 of them above the price). That is a moderate margin of safety: the stock passes the "below fair value" rule of the Sunday Scan, and the Wheel Score gives it 18 of the 25 Value points.
There is a wide gap between Graham Number (50.01) and GLS Growth (331.55). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files PODD under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for PODD
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 50.01 | -63% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 227.94 | +70% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 93.54 | -30% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 331.55 | +148% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 138.95 | +4% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 170.45 | +27% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 60.17 | -55% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 3.08 | -98% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 182.78 | +36% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Insulet Corp. scores 9 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the Sunday Scan's "6 or more" rule with room to spare. On durability PODD scores 6.7/10 on the GLS Moat - a middle reading; the Scorecard on the Quote page's Financials tab shows which ten-year lines are steady and which are not.
Returns on capital are moderate - ROIC 9.6%, ROE 16.3%, ROA 7.7% - with debt at 0.69 times equity and a free-cash-flow yield of 3.2%.
Insulet Corp. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from International Omnipod 99%, Drug Delivery 1% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 9/10 and Congressional trading 4/10 on the GLS smart-money scales; the last recorded Congressional buy was on 18 Aug 2026.
| Piotroski F-score | 9 / 9 | ROIC | 9.6% |
|---|---|---|---|
| GLS Moat | 6.7 / 10 | ROE | 16.3% |
| Debt / equity | 0.69 | ROA | 7.7% |
| Free-cash-flow yield | 3.2% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 9 · 4 / 10 |
Wheel Score 88: Prime
With a Wheel Score of 88, Insulet Corp. sits in the Prime band - price, quality and premium all line up for the wheel strategy. The parts: Value 18/25, Health 20/20, Moat 10/15, Premium 20/20, Stability 20/20. A high score is a ranking, not a signal: it says nothing about timing, the earnings date or your position size.
Implied volatility is 55% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 11,339 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 2.3M shares a day on a market cap of $9.3B, with a beta of 1.10; the Stability part of the Wheel Score gives that 20 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 18 / 25 | 13% margin of safety | |
| Health | 20 / 20 | Piotroski 9/9 | |
| Moat | 10 / 15 | moat 6.7/10 | |
| Premium | 20 / 20 | implied volatility 55% | |
| Stability | 20 / 20 | 2.3M shares/day, $9.3B cap, beta 1.10 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 4 Nov 2026 (before the open), 19 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Devices
The 12 companies below are the closest to Insulet Corp. by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| GKOS Glaukos Corporation | 165.60 | - | - | 45Weak | $9.8B |
| BIO Bio-Rad Laboratories, Inc. | 364.82 | 246.29 | -48% | 58Fair | $9.8B |
| BRKR Bruker Corporation | 56.54 | 18.80 | -201% | 45Weak | $8.6B |
| BRKRP Bruker Corporation | 417.62 | 27.00 | -1447% | 28No options | $8.6B |
| GMED Globus Medical, Inc. | 78.84 | 112.94 | +30% | 92Prime | $10.6B |
| ALGN Align Technology, Inc. | 149.34 | 125.50 | -19% | 66Good | $10.6B |
| SNN Smith & Nephew plc | 27.88 | 37.94 | +27% | 90Prime | $11.7B |
| PEN Penumbra, Inc. | 320.12 | 139.38 | -130% | 54Fair | $12.6B |
| HAE Haemonetics Corporation | 121.29 | 65.74 | -84% | 60Fair | $5.5B |
| ZBH Zimmer Biomet Holdings, Inc. | 91.77 | 134.51 | +32% | 87Prime | $17.5B |
| LIVN LivaNova PLC | 78.50 | 99.67 | +21% | 82Prime | $4.3B |
| ITGR Integer Holdings Corporation | 126.72 | 78.09 | -62% | 47Weak | $4.3B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about PODD
Is PODD undervalued right now?
By the GLS models, moderately: at 133.93 the stock trades 13% below the average fair value of 153.23 (data as of 16 Oct 2026).
What is the Wheel Score of PODD and what does it mean?
PODD scores 88 out of 100 (Prime). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for PODD?
153.23 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Insulet Corp. report earnings next?
The next earnings report is due on 4 Nov 2026 (before the open), 19 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does PODD have listed options, and how liquid are they?
Yes. The nightly snapshot found 372 listed contracts with 11,339 open interest across all expiries and implied volatility of 55% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.